Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
Exp Dermatol ; 32(10): 1744-1751, 2023 10.
Article in English | MEDLINE | ID: mdl-37534916

ABSTRACT

In dermatology, deep learning may be applied for skin lesion classification. However, for a given input image, a neural network only outputs a label, obtained using the class probabilities, which do not model uncertainty. Our group developed a novel method to quantify uncertainty in stochastic neural networks. In this study, we aimed to train such network for skin lesion classification and evaluate its diagnostic performance and uncertainty, and compare the results to the assessments by a group of dermatologists. By passing duplicates of an image through such a stochastic neural network, we obtained distributions per class, rather than a single probability value. We interpreted the overlap between these distributions as the output uncertainty, where a high overlap indicated a high uncertainty, and vice versa. We had 29 dermatologists diagnose a series of skin lesions and rate their confidence. We compared these results to those of the network. The network achieved a sensitivity and specificity of 50% and 88%, comparable to the average dermatologist (respectively 68% and 73%). Higher confidence/less uncertainty was associated with better diagnostic performance both in the neural network and in dermatologists. We found no correlation between the uncertainty of the neural network and the confidence of dermatologists (R = -0.06, p = 0.77). Dermatologists should not blindly trust the output of a neural network, especially when its uncertainty is high. The addition of an uncertainty score may stimulate the human-computer interaction.


Subject(s)
Artificial Intelligence , Dermatologists , Dermoscopy , Skin Diseases , Humans , Dermoscopy/methods , Melanoma/diagnostic imaging , Melanoma/pathology , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/pathology , Skin Diseases/diagnostic imaging , Skin Diseases/pathology
4.
Skin Res Technol ; 26(5): 708-712, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32227367

ABSTRACT

BACKGROUND AND OBJECTIVES: Dermoscopy has proven its value in the diagnosis of skin cancer and, therefore, is well established in daily dermatology practice. Up until now, analogue white light dermoscopy is the standard. Multispectral dermoscopy is based on illumination of the skin with narrowband light sources with different wavelengths. Each of these wavelengths is differently absorbed by skin chromophores, such as pigment or (de)oxygenated blood. Multispectral dermoscopy could be a way to enhance the visualization of vasculature and pigment. We illustrate possible additional information by such "skin parameter maps" in some cases of basal cell carcinoma and Bowen's disease. METHODS: Using a new digital multispectral dermatoscope, skin images at multiple wavelengths are collected from different types of skin lesions. These particular images together with the knowledge on skin absorption properties, result in so called "skin parameter maps". RESULTS: A "pigment contrast map," which shows the relative concentration of primarily pigment, and a "blood contrast map" which shows the relative concentration of primarily blood were created. Especially, the latter is of importance in diagnosing keratinocyte skin cancer hence vascular structures are a characteristic feature, as further illustrated in the study. CONCLUSIONS: Skin parameter maps based on multispectral images can give better insight in the inner structures of lesions, especially in lesions with characteristic blood vessels such as Bowen's disease and basal cell carcinoma. Skin parameter maps can be used complementary to regular dermoscopy and could potentially facilitate diagnosing skin lesions.


Subject(s)
Bowen's Disease , Carcinoma, Basal Cell , Dermoscopy , Skin Neoplasms , Bowen's Disease/diagnostic imaging , Carcinoma, Basal Cell/diagnostic imaging , Diagnosis, Differential , Humans , Skin/blood supply , Skin/diagnostic imaging , Skin Neoplasms/diagnostic imaging , Skin Pigmentation
5.
Acta Orthop Belg ; 86(2): 200-204, 2020 Jun.
Article in English | MEDLINE | ID: mdl-33418607

ABSTRACT

We present a case of Nocardia farcinica after placement of reverse shoulder prosthesis in a 73-year-old woman. One month after surgery, the patient was admitted to the hospital with a spontaneous drainage of the wound and complaints of aggravating pain in the operated shoulder. There was no history of an immunosuppressive disease or therapy. After cultivation and empiric therapy with flucloxacillin, Nocardia farcinica was found and treated with a combination of intravenous amikacin and ceftriaxone. Eight days after drainage, a rinse and replacement of the polyethylene cup and glenosphere was executed. The treatment was proven to be successful whereas X-ray scans showed no complications nor any other consequences up until five years after therapy. To our knowledge, this is the first shoulder prosthetic Nocardia infection published in English literature. The aim of this report is to review/gather the knowledge about this particular infection and inform health care providers about this uncommon case.


Subject(s)
Amikacin/administration & dosage , Arthroplasty, Replacement, Shoulder/adverse effects , Ceftriaxone/administration & dosage , Nocardia Infections , Nocardia/isolation & purification , Prosthesis-Related Infections , Reoperation/methods , Shoulder Prosthesis/adverse effects , Administration, Intravenous , Aged , Anti-Bacterial Agents/administration & dosage , Arthroplasty, Replacement, Shoulder/instrumentation , Arthroplasty, Replacement, Shoulder/methods , Female , Humans , Nocardia Infections/drug therapy , Nocardia Infections/etiology , Nocardia Infections/surgery , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/etiology , Prosthesis-Related Infections/microbiology , Prosthesis-Related Infections/surgery , Treatment Outcome
6.
Pigment Cell Melanoma Res ; 32(6): 842-847, 2019 11.
Article in English | MEDLINE | ID: mdl-31063266

ABSTRACT

Multiple reports confirm elevated circulating IL-17 levels and increased numbers of Th17 lymphocytes in patients with non-segmental vitiligo. Additionally, melanocyte damaging characteristics have been ascribed to IL-17. A single-arm pilot study using secukinumab in active non-segmental vitiligo was conducted. The large majority of patients developed additional skin depigmentations limiting further enrollment. Overall, laboratory analysis revealed no change in secreted chemokines or Th subsets. Th17 lymphocytes correlated with Th2, Th9, and Th22 cells while an inverse link with Th1 cells and serum sCD25 levels was observed. In contrast, Th17.1 cells correlated positively with Th1 lymphocytes. Confirmatory results were found in an independent group of patients with vitiligo showing a significant increase in Th17.1 and Th1 lymphocytes in progressive vitiligo patients compared to healthy controls, which was not found for Th17 cells. These results do not support a direct pathogenic role of IL-17 or Th17 cells in vitiligo. Nonetheless, a delicate Th17/Th17.1/Th1 balance seems evident which changes markedly according to disease activity. This may offer new treatment options by interfering with cytokines that drive differentiation of Th17 cells toward Th1.


Subject(s)
Disease Progression , Interleukin-17/metabolism , Molecular Targeted Therapy , Vitiligo/drug therapy , Vitiligo/pathology , Adult , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Humans , Lymphocyte Subsets/drug effects , Lymphocyte Subsets/immunology , Middle Aged , Th17 Cells/drug effects , Th17 Cells/immunology
7.
Am J Clin Dermatol ; 19(5): 625-637, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30003497

ABSTRACT

New promising treatments have been developed for psoriasis that target different parts of the interleukin (IL)-23/IL-17 pathway. This approach is believed to be more disease specific, and sparing the T helper 1 pathway might prevent serious long-term adverse events. Moreover, superior Psoriasis Area and Severity Index improvements are observed, which has redefined treatment goals in psoriasis. The new molecules can be divided into different categories, according to the target: blocking agents can target the upstream cytokine IL-23 or the downstream IL-17. In the latter, a variety of targets exist, such as the ligands IL-17A and IL-17F, or a combination thereof, or a subunit of the receptor, IL-17RA. Each target seems to have its own set of advantages and pitfalls, which will impact the treatment decision in clinical practice. In this review, we summarize the current knowledge on the different inhibitors of the IL-23/IL-17 pathway. Furthermore, we briefly discuss the role of IL-17 in other diseases and comorbidities. Finally, we discuss how comprehensive knowledge is needed for the prescribing physician in order to make the most appropriate therapeutic choice for each individual patient.


Subject(s)
Immunosuppressive Agents/therapeutic use , Interleukin-17/antagonists & inhibitors , Interleukin-23/antagonists & inhibitors , Molecular Targeted Therapy , Psoriasis/drug therapy , Signal Transduction/drug effects , Humans , Immunosuppressive Agents/pharmacology , Interleukin-17/immunology , Interleukin-17/metabolism , Interleukin-23/immunology , Interleukin-23/metabolism , Patient Selection , Psoriasis/diagnosis , Psoriasis/immunology , Receptors, Interleukin-17/antagonists & inhibitors , Receptors, Interleukin-17/immunology , Receptors, Interleukin-17/metabolism , Severity of Illness Index , Signal Transduction/immunology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...